Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure

The American Journal of Cardiology
Kenneth DicksteinPaul A Koopman

Abstract

SLV306, a potent neutral endopeptidase (NEP) inhibitor with additional endothelin-converting enzyme (ECE)-inhibitory activity, in doses of 200, 400, and 800 mg reduced pulmonary and right atrial pressures, although there was not a clear dose response. Systemic blood pressure, heart rate, and cardiac output were unaffected. SLV306 increased plasma natriuretic peptides and big endothelin-1 levels in a dose-dependent manner, confirming NEP and ECE inhibition. The combined inhibition of NEP and ECE may be useful in heart failure by reducing right and left cardiac filling pressures.

Citations

Sep 19, 2009·Heart Failure Reviews·Navneet S Rehsia, Naranjan S Dhalla
Jan 26, 2010·Expert Opinion on Emerging Drugs·Reda E Girgis
Mar 10, 2016·Pharmacological Reviews·Anthony P DavenportJanet J Maguire
May 20, 2014·Pharmacology & Therapeutics·Thomas G von LuederHenry Krum
Aug 19, 2014·British Journal of Pharmacology·J J Maguire, A P Davenport
Oct 27, 2004·Expert Review of Cardiovascular Therapy·John V Wylie, Lana Tsao
May 18, 2010·Journal of Cardiovascular Pharmacology and Therapeutics·Katherine C Wu, Gary Gerstenblith
Mar 21, 2012·Nature Reviews. Cardiology·Ludovit PaulisThomas Unger
Mar 15, 2015·Circulation Research·Suzanne Oparil, Roland E Schmieder
Sep 20, 2007·Journal of Cardiovascular Pharmacology·Philippe DaullBruno Battistini
Nov 14, 2013·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Matthieu MongeMichel Azizi
Mar 11, 2020·Clinica Chimica Acta; International Journal of Clinical Chemistry·Eray ErogluBengt Lindholm

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.